CAPTOPRIL INDUCES CORRECTION OF POSTRENAL TRANSPLANT ERYTHREMIA

被引：29

作者：

ISLAM, MS ^{[1
]}

BOURBIGOT, B ^{[1
]}

CODET, JP ^{[1
]}

SONGY, B ^{[1
]}

FOURNIER, G ^{[1
]}

CLEDES, J ^{[1
]}

机构：

[1] CHU MORVAN,SERV NEPHROL,5 AVE FOCH,F-29285 BREST,FRANCE

来源：

TRANSPLANT INTERNATIONAL | 1990年 / 3卷 / 04期

关键词：

ERYTHREMIA; POSTTRANSPLANTATION CAPTOPRIL;

D O I：

10.1111/j.1432-2277.1990.tb01928.x

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Kidney transplant patients may develop post-transplant erythremia (PTE), and in order to avoid thromboembolism venesection, anticoagulation and native kidney removal have been suggested. We propose captopril as an alternative therapy for PTE. Seven hypertensive PTE patients, aged 42 +/- 10 years with stable renal function, were investigated to exclude primary or secondary polycythemia. All patients manifested true erythrocytosis [red blood cells (RBC) mass > 20% of predicted level] with concomitant increases in hematocrit and hemoglobin levels. Captopril was introduced in gradually increasing doses up to 75 mg/day under careful monitoring of blood pressure and renal function. Weekly follow-up was arranged to evaluate drug efficacy. After captopril, a significant reduction with normalization of the RBC mass (42 +/- 4 vs 31 +/- 5 ml/kg; P < 0.005) was observed. The RBC counts and hematocrit and hemoglobin levels also decreased. One patient had recurrent erythrocytosis after captopril withdrawal. Captopril may be a simple, effective, and non aggressive treatment for postrenal transplant erythremia.

引用

页码：222 / 225

页数：4